Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AstraZeneca (Paludrine, Avlocor, Savarine)

AstraZeneca (Paludrine, Avlocor, Savarine)
M&A STATUS
5K-10K EMPLOYEES
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of antimalarial medication brands. The company consists of three antimalarial brands, Paludrine, Avloclor, Savarine developed by AstraZeneca UK Limited.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Primary Office
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge CB2 0AA
  • England, United Kingdom

AstraZeneca (Paludrine, Avlocor, Savarine) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore AstraZeneca (Paludrine, Avlocor, Savarine)‘s full profile, request access.

Request full access to PitchBook

AstraZeneca (Paludrine, Avlocor, Savarine) Executive Team (1)

Name Title Board
Seat
Contact
Info
Peter Selley President & Chief Executive Officer